Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/30583
DC FieldValueLanguage
dc.contributor.authorGradiz, Rui-
dc.contributor.authorSilva, Henriqueta C-
dc.contributor.authorCarvalho, Lina-
dc.contributor.authorBotelho, Maria Filomena-
dc.contributor.authorMota-Pinto, Anabela-
dc.date.accessioned2016-02-19T11:35:11Z-
dc.date.available2016-02-19T11:35:11Z-
dc.date.issued2016-02-17-
dc.identifier.urihttp://hdl.handle.net/10316/30583-
dc.description.abstractStudies using cell lines should always characterize these cells to ensure that the results are not distorted by unexpected morphological or genetic changes possibly due to culture time or passage number. Thus, the aim of this study was to describe those MIA PaCa-2 and PANC-1 cell line phenotype and genotype characteristics that may play a crucial role in pancreatic cancer therapeutic assays, namely neuroendocrine chemotherapy and peptide receptor radionuclide therapy. Epithelial, mesenchymal, endocrine and stem cell marker characterization was performed by immunohistochemistry and flow cytometry, and genotyping by PCR, gene sequencing and capillary electrophoresis. MIA PaCa-2 (polymorphism) expresses CK5.6, AE1/AE3, E-cadherin, vimentin, chromogranin A, synaptophysin, SSTR2 and NTR1 but not CD56. PANC-1 (pleomorphism) expresses CK5.6, MNF-116, vimentin, chromogranin A, CD56 and SSTR2 but not E-cadherin, synaptophysin or NTR1. MIA PaCA-1 is CD24−, CD44+/++, CD326−/+ and CD133/1− , while PANC-1 is CD24−/+, CD44+, CD326−/+ and CD133/1−. Both cell lines have KRAS and TP53 mutations and homozygous deletions including the first 3 exons of CDKN2A/ p16INK4A, but no SMAD4/DPC4 mutations or microsatellite instability. Both have neuroendocrine differentiation and SSTR2 receptors, precisely the features making them suitable for the therapies we propose to assay in future studies.por
dc.language.isoengpor
dc.rightsopenAccesspor
dc.subjectMIA Paca-2por
dc.subjectPANC-1por
dc.subjectPancreaspor
dc.titleMIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptorspor
dc.typearticlepor
degois.publication.firstPage1por
degois.publication.lastPage14por
degois.publication.issue21648por
degois.publication.titleScientific Reportspor
dc.relation.publisherversionhttp://www.nature.com/srep/articles?&page=5por
dc.peerreviewedYespor
degois.publication.volume6por
item.grantfulltextopen-
item.languageiso639-1en-
item.fulltextCom Texto completo-
crisitem.author.deptFaculdade de Medicina, Universidade de Coimbra-
crisitem.author.deptFaculdade de Medicina, Universidade de Coimbra-
crisitem.author.researchunitiNOVA4Health - Programme in Translational Medicine (iBET, CEDOC/FCM, IPOLFG and ITQB)-
crisitem.author.researchunitCNC.IBILI-
crisitem.author.orcid0000-0001-8349-4488-
crisitem.author.orcid0000-0001-7202-1650-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
Show simple item record

Page view(s)

209
checked on Sep 17, 2019

Download(s) 50

176
checked on Sep 17, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.